BioRestorative Therapies, Inc.
General ticker "BRTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $12.9M (TTM average)
BioRestorative Therapies, Inc. does not follow the US Stock Market performance with the rate: -5.5%.
Estimated limits based on current volatility of 4.8%: low 1.03$, high 1.14$
Factors to consider:
- Total employees count: 4 as of 2011
- Top business risk factors: Limited operating history and ongoing losses, Substantial financing needs, Product development delays, Labor/talent shortage/retention, Market acceptance of new products
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.76$, 2.73$]
- 2025-12-31 to 2026-12-31 estimated range: [0.41$, 1.61$]
Financial Metrics affecting the BRTX estimates:
- Positive: with PPE of -1.1 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -70.99 <= 0.33
- Positive: Shareholder equity ratio, % of 69.48 > 63.39
- Negative: negative Industry operating cash flow (median)
- Positive: Investing cash flow per share per price, % of 4.44 > -0.66
- Positive: Inventory ratio change, % of 0 <= 0
- Negative: negative Net income
Short-term BRTX quotes
Long-term BRTX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.12MM | $0.15MM | $0.40MM |
| Operating Expenses | $19.09MM | $15.37MM | $11.96MM |
| Operating Income | $-18.97MM | $-15.22MM | $-11.56MM |
| Non-Operating Income | $5.75MM | $4.80MM | $2.58MM |
| R&D Expense | $3.51MM | $4.03MM | $5.35MM |
| Income(Loss) | $-13.22MM | $-10.42MM | $-8.98MM |
| Profit(Loss)* | $-13.22MM | $-10.42MM | $-8.98MM |
| Stockholders Equity | $10.29MM | $10.00MM | $8.53MM |
| Assets | $16.43MM | $12.61MM | $12.28MM |
| Operating Cash Flow | $-5.91MM | $-6.43MM | $-8.23MM |
| Capital expenditure | $0.44MM | $0.17MM | $0.11MM |
| Investing Cash Flow | $-13.40MM | $3.25MM | $0.51MM |
| Financing Cash Flow | $0.00MM | $2.35MM | $7.38MM |
| Earnings Per Share** | $-3.65 | $-2.47 | $-1.16 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.